UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

Drug and alcohol dependence reports, 2023-03, Vol.6, p.100133-100133, Article 100133

2023

Link zum Volltext

Verfügbarkeit prüfen

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS

Drug and alcohol dependence, 2021-12, Vol.229 (Pt B), p.109057-109057, Article 109057

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

Clinical pharmacokinetics, 2015-08, Vol.54 (8), p.837-849

2015

Link zum Volltext

Verfügbarkeit prüfen

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

Journal of clinical psychopharmacology, 2016-02, Vol.36 (1), p.18-26

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study

Journal of clinical psychopharmacology, 2016-04, Vol.36 (2), p.130-140

2016

Link zum Volltext

Verfügbarkeit prüfen

Buprenorphine: Considerations for Pain Management

Journal of pain and symptom management, 2005-03, Vol.29 (3), p.297-326

2005

Link zum Volltext

Verfügbarkeit prüfen

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

The New England journal of medicine, 2003-09, Vol.349 (10), p.949-958

2003

Link zum Volltext

Verfügbarkeit prüfen

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

Journal of clinical psychopharmacology, 2020-05, Vol.40 (3), p.231

2020

Link zum Volltext

Verfügbarkeit prüfen

A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

Clinical pharmacokinetics, 2014-09, Vol.53 (9), p.813-824

2014

Link zum Volltext

Verfügbarkeit prüfen

Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument

Drug and alcohol dependence, 2009-11, Vol.105 (1), p.154-159

2009

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

Clinical pharmacokinetics, 2014-06, Vol.53 (6), p.533-543

2014

Link zum Volltext

Verfügbarkeit prüfen

Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine

Addiction (Abingdon, England), 1998-04, Vol.93 (4), p.549-559

1998

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone

Journal of clinical pharmacology, 2015-01, Vol.55 (1), p.93-103

2015

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects

Journal of addictive diseases, 2014-10, Vol.33 (4), p.289-302

2014

Link zum Volltext

Verfügbarkeit prüfen

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users

Addiction (Abingdon, England), 2005-02, Vol.100 (2), p.150-158

2005

Link zum Volltext

Verfügbarkeit prüfen

Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals

Drug and alcohol dependence, 2009-07, Vol.103 (1), p.59-64

2009

Link zum Volltext

Verfügbarkeit prüfen

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (−)ecgonine methyl ester in human acidified stabilized plasma samples

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2014-06, Vol.961, p.77-85

2014

Link zum Volltext

Verfügbarkeit prüfen

Development of opioid formulations with limited diversion and abuse potential

Drug and alcohol dependence, 2006-06, Vol.83, p.S40-S47

2006

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

Clinical pharmacology and therapeutics, 2004-01, Vol.75 (1), p.34-48

2004

Link zum Volltext

Verfügbarkeit prüfen

A controlled trial of buprenorphine treatment for opioid dependence

JAMA : the journal of the American Medical Association, 1992-05, Vol.267 (20), p.2750

1992

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2019-02, Vol.393 (10173), p.778-790

2019

Link zum Volltext

Verfügbarkeit prüfen

Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence

Drug and alcohol dependence, 2006-12, Vol.85 (3), p.191-197

2006

Link zum Volltext

Verfügbarkeit prüfen

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence

Drug and Alcohol Dependence, 2003-05, Vol.70 (2), p.S79-S85

2003

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in the treatment of opiate addiction

Current psychiatry reports, 2004-10, Vol.6 (5), p.339-346

2004

Link zum Volltext

Verfügbarkeit prüfen

A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids

Drug and alcohol dependence, 1994-10, Vol.36 (2), p.115-121

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(71)
Buchkapitel
(1)

Sprache

Englisch
(72)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(52)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Male
(41)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Adult
(32)
Female
(27)
Psychiatry
(24)
Middle Aged
(22)
Substance Abuse
(22)
Double-Blind Method
(18)
Pharmacology & Pharmacy
(17)
Buprenorphine - Therapeutic Use
(16)
Psychology. Psychoanalysis. Psychiatry
(16)
Toxicology
(16)
Drug Addictions
(14)
Psychopathology. Psychiatry
(14)
Buprenorphine
(13)
Buprenorphine - Administration & Dosage
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study

Buprenorphine: Considerations for Pain Management

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine

Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone

A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users

Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (−)ecgonine methyl ester in human acidified stabilized plasma samples

Development of opioid formulations with limited diversion and abuse potential

Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

A controlled trial of buprenorphine treatment for opioid dependence

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence

Recent advances in the treatment of opiate addiction

A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids

Suchergebnisse filtern